ArticleJournal of clinical medicine2024

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.

Shuzo Hamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.